PolarityBio Announces Interim Enrollment Achieved in SkinTE’s Phase III Pivotal Study
Interim Analysis Anticipated at end of Q1 2025 SALT LAKE CITY, Dec. 03, 2024 (GLOBE NEWSWIRE) -- PolarityBio, a clinical-stage biotechnology company developing regenerative tissue products, today announced that it has surpassed the interim enrollment …